DLBCL

There are multiple treatment options becoming available for diffuse large B-cell lymphoma, but more work needs to be done to understand their efficacy and in what lines of therapy they should be used.

Even patients with diffuse large B-cell lymphoma who are eligible for chimeric antigen receptor (CAR) T-cell therapy face multiple barriers to care and need assistance.

Although B-cell lymphomas can be challenging to study, there have been great advances in treatments in the second-line and later, explained Kami Maddocks, MD, professor of Clinical Internal Medicine, the Ohio State James Comprehensive Cancer Center.

Chimeric antigen receptor T-cell therapies are already moving into earlier lines of therapy for patients with diffuse large B-cell lymphoma (DLBCL), and now people are looking at when to use bispecific antibodies.

There are various immunotherapies being used in the second ling for patients with lymphomas, some of which have curative potential, explained Christopher Flowers, MD, MS, of the University of Texas MD Anderson Cancer Center.

In this interview, Tycel Phillips, MD, associate professor of medicine, Division of Lymphoma and Bone Marrow Transplantation, City of Hope, Duarte, California, discusses the advancements that are shaping the future of B-cell lymphoma treatment, as well as access barriers.

Nearly 5 years after approval of the first CAR T-cell therapy, treatment is moving into second line, and patients have more options than ever for diffuse large B-cell lymphoma. How do physicians choose? Bita Fakhri, MD, MPH, hematologist-oncologist at the University of California San Francisco, discusses the process.

Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue.

Andrew Zelenetz, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, is the current chair of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network (NCCN).

Julio Chavez, MD, MS, of Moffitt Cancer Center, spoke with The American Journal of Managed Care® (AJMC®) about how new approvals will alter decision making in the treatment of diffuse large B-cell lymphoma (DLBCL).

Kami J. Maddocks, MD, professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, spoke with The American Journal of Managed Care® (AJMC®) about treatment approaches for diffuse large B-cell lymphoma (DLBCL).